Moderna signs deal to supply COVID-19 vaccine to UK from March

By: |
Updated: Nov 17, 2020 8:36 PM

The company's statement did not disclose other terms of the agreement, including the number of doses it agreed to supply.

The company did not disclose other terms of the agreement, including the number of doses it agreed to supply.Moderna on Monday said mRNA-1273 was 94.5% effective in preventing COVID-19 based on interim data from its late-stage clinical trial.

Moderna Inc confirmed on Tuesday it had agreed to supply its COVID-19 vaccine candidate, mRNA-1273, to the United Kingdom starting from the beginning of March, as long as it succeeds in gaining local regulatory approval.

The company’s statement did not disclose other terms of the agreement, including the number of doses it agreed to supply.

UK Health Minister Matt Hancock told a news conference on Monday that the deal would see the U.S. startup, one of two vaccine makers who have so far published positive data on final-stage trials, supply five million doses from next spring.

Moderna on Monday said mRNA-1273 was 94.5% effective in preventing COVID-19 based on interim data from its late-stage clinical trial.

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) in October started a real-time review of the vaccine candidate, a process which allows for a faster approval of a treatment.

The company on Tuesday also said it was on track to deliver about 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021.

It has tied up with manufacturing partners Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States, to supply the vaccine to Europe and other countries outside U.S.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covishield: SII refutes adverse reaction claim, seeks Rs 100-cr in damages
2IMA offers govt services of its members in COVID-19 inoculation programme
3Serum Institute rejects charges levelled by vaccine trial participant, threatens to seek damages